Research & Education

7th Webinar: IASLC Grand Rounds Series - Surgery for N2 - What, When and How

July 24, 2014 - Recording Now Available

The Seventh webinar in the series: IASLC Grand Rounds Series - Surgery for N2 - What, When and How took place on July 24, 2014 at 8:00PM EDT.

Eric Vallières, MD, FRCSC
Surgical Director of the Lung Cancer Program
Medical Director Division of Thoracic Surgery
Swedish Cancer Institute

Ramaswamy Govindan, MD - Program Chair
Co-Director, Section of Medical Oncology
Professor of Medicine
Division of Oncology
Washington University School of Medicine

The IASLC Lung Cancer Grand Rounds Webinar Series continues on July 24, 2014. The management of clinical stage IIIA N2 NSCLC remains a subject of debate, in part because stage IIIA encompasses such a wide variety of disease. Combined modality treatments are the rule but the recommended modalities vary as do their sequence; chemotherapy, either upfront or in the adjuvant setting being the only part of the treatment that is universal. Large phase III trials in Europe and America that have compared chemoradiation therapy approaches to strategies that have incorporated surgical resection have questioned the role of surgery in clinical stage IIIA N2 NSCLC. By design, however, these trials did not account for the heterogeneity of the disease and their conclusions have been argued. This webinar will review the possible therapeutic indications of surgical resection and its limitations in the management of clinical stage IIIA N2 NSCLC.

Objectives/ key points: At the end of this presentation the participant will recognize that:

  1. Stage IIIA NSCLC is a heterogeneous group of lung cancers with different degrees of lymph node involvement
  2. Patients with clinical stage IIIA non-small cell lung cancer should be evaluated in a multidisciplinary setting including early evaluation by a thoracic surgeon who dedicates most of his or her practice to lung cancer therapy
  3. Some patients with clinically stage IIIA can be treated with induction therapy followed by surgery while others are best offered definitive chemoradiotherapy
  4. There is inadequate data from randomized trials to inform on the optimal treatment strategy in stage IIIA NSCLC, particularly in patients with non-bulky nodal disease.
  5. Chemotherapy should be part of the therapy of all patients with stage IIIA disease who are able to receive cisplatin based chemotherapy 

Following Dr. Vallieres' presentation,  there will be ample opportunity for Dr. Vallieres and Dr. Govindan to address questions and comments submitted by the audience via internet chat.

Recording Available


This CME live webinar series is designed to meet the educational needs of healthcare professionals who diagnose and treat patients with lung cancer, including medical oncologists, thoracic surgeons, pulmonologists, radiation oncologists, radiologists, pathologists and advanced practice nurses and physicians' assistants. Participants who complete a pre-and post-test along with an evaluation will receive 1 AMA PRA Category 1 CreditTM for each completed webinar.

If you are interested in obtaining the CME Credits for these sessions you must indicate this when you register for the program.

This series is supported in part by unrestricted educational grants provided by Bristol-Myers Squibb Co., Celgene and Genentech